ClinicalTrials.gg
RecruitingNCT07750873CALIBRATE-HFUpdated Aug 6, 2026

A Trial of CRD-4730 in HFrEF

A Phase 2 interventional study of CRD-4730 and Placebo in Heart Failure With Reduced Ejection Fraction (HFrEF), sponsored by Cardurion Pharmaceuticals, Inc.. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by Cardurion Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
525
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,157 studies in Heart Failure with a site in United States — 347 open to participants now, 437 under way, 27 of them phase 3. Heart Failure · United States.

Planned enrollment
241st of 1,601
525 · median 65
Started
2026
with 94 others
Phase 2
227 of 2,157
26 open now
Primary completion
2028-09
later than 329 of 436 live
Registered
2,132nd of 2,157
by date

Among the 2,157 studies in Heart Failure with a site in United States, this one is the 241st largest by planned enrollment of the 1,601 interventional ones that give a count, is one of 95 that started in 2026, is one of 227 in phase 2, reaches primary completion later than 329 of the 436 other live ones, and was the 2,132nd registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

347 of the 2,157 studies in Heart Failure with a site in United States are open now. Recruiting first, the newest first:

342 more — sign in →

All 347 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,157 studies in Heart Failure with a site in United States, or all of them as a file.
02

Study summary

CRD-4730 is a calcium/calmodulin-dependent protein kinase II (CaMKII) inhibitor. The CALIBRATE-HF trial is a Phase 2, global, multi-center, randomized, double-blind, parallel-group, placebo-controlled trial. The trial will evaluate the efficacy, safety, and tolerability of CRD-4730 in addition to guideline directed medical therapy in participants with heart failure with reduced ejection fraction (HFrEF). Participants will be randomized to 1 of 4 study groups and receive investigational study drug or placebo twice daily (BID) for 24 weeks of treatment.

03

Conditions studied

  • Heart Failure With Reduced Ejection Fraction (HFrEF)

Browse trials for

Keywords

  • Heart failure
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult male or female patient ≥ 18 years of age and ≤ 85 years of age at the time of screening.
  • Has a medical history supporting a diagnosis of clinical chronic heart failure (HF) syndrome with a duration of at least 8 weeks prior to the time of screening and current functional class II to III (based on investigator's assessment).
  • Has ≤ 40% by a centrally read transthoracic echocardiogram performed during screening.
  • Has NT-proBNP level ≥ 600 pg/mL (70.8 pmol/L) at the time of screening. Patients in atrial fibrillation or flutter at the time of screening are required to have an NT-proBNP level of ≥ 900 pg/mL (106.4 pmol/L).
  • Is receiving optimized and stable guideline directed HF therapy (per applicable regional or national guidelines).

Exclusion criteria

Exclusion Criteria:

  • Has evidence of recent HF exacerbation defined by hospitalization or requirement for IV or SQ diuretics within 4 weeks of the time of screening or during the Screening Period.
  • Has a requirement for routine, scheduled outpatient IV infusions for HF (ie, inotropes, vasodilators, or diuretics) or routinely scheduled ultrafiltration.
  • Has acute coronary syndrome, unstable angina, persistent angina at rest, stroke, , cardiac, carotid or other major cardiovascular surgery, cardiac valve repair (surgical or nonsurgical) or surgical replacement, or carotid angioplasty within 8 weeks prior to screening or during the Screening Period.
  • Has clinical suspicion of infiltrative cardiomyopathy (eg, amyloid, sarcoid), hypertrophic cardiomyopathy (obstructive or non-obstructive), or HF secondary to severe valvular disease, active myocarditis, active pericarditis, or congenital heart disease.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
525 participants (estimated)

Study arms

  • Experimental
    Study Arm 1: CRD-4730 Dose A tablet

    Participants will receive Dose A of CRD-4730 administered orally twice daily for 24 weeks

    Drug: CRD-4730

  • Experimental
    Study Arm 2: CRD-4730 Dose B tablet

    Participants will receive Dose B of CRD-4730 administered orally twice daily for 24 weeks

    Drug: CRD-4730

  • Experimental
    Study Arm 3: CRD-4730 Dose C tablet

    Participants will receive Dose C of CRD-4730 administered orally twice daily for 24 weeks

    Drug: CRD-4730

  • Placebo comparator
    Study Arm 4: Matched Placebo tablet

    Participants will receive placebo administered orally twice daily for 24 weeks

    Drug: Placebo

Interventions

  • Experimental, Dose A, B and C

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Composite Z-Score at 24 weeks

    Composite Z-score calculated as the average of Z-scores for the change from baseline at 24 weeks for the following 6 endpoints: NT-proBNP (log-transformed), Left ventricular end-diastolic volume index (LVEDVI), Left ventricular end-systolic volume index (LVESVI), E/e' ratio, Global longitudinal strain (GLS), Left atrial volume index (LAVI). A z-score for each component endpoint is a standardized measure with a common scale with a mean of 0 and a standard deviation of 1. Composite z-score integrates the component z-scores to assess a participant's overall response. Lower composite z-scores indicate more favorable changes from baseline, whereas higher composite z-scores indicate less favorable changes from baseline.

    Time frame: Baseline and Week 24

Secondary outcomes

  1. NT-proBNP biomarker

    Change in NT-proBNP (measured in pg/mL) from baseline at 12 and 24 weeks.

    Time frame: Baseline, Week 12, and Week 24

  2. Left ventricular end-diastolic volume

    Change from baseline in left ventricular end-diastolic volume (LVEDV, measured in mL) at 12 and 24 weeks

    Time frame: Baseline, Week 12, and Week 24

  3. Left ventricular end-diastolic volume index

    Change from baseline in left ventricular end-diastolic volume index (LVEDVI, measured in mL/m²) at 12 and 24 weeks

    Time frame: Baseline, Week 12, and Week 24

  4. Left ventricular end-systolic volume

    Change from baseline in left ventricular end-systolic volume (LVESV, measured in mL) at 12 and 24 weeks

    Time frame: Baseline, Week 12, and Week 24

  5. Left ventricular end-systolic volume index

    Change from baseline in left ventricular end-systolic volume index (LVESVI, measured in mL/m²) at 12 and 24 weeks

    Time frame: Baseline, Week 12, and Week 24

  6. Early diastolic mitral inflow velocity (E)/early diastolic mitral annular velocity (e') ratio

    Change from baseline in early diastolic mitral inflow velocity (E)/early diastolic mitral annular velocity (e') ratio (E/e' ratio, unitless) at 12 and 24 weeks

    Time frame: Baseline, Week 12, and Week 24

  7. Global longitudinal strain

    Change from baseline in global longitudinal strain (GLS, measured in %) at 12 and 24 weeks

    Time frame: Baseline, Week 12, and Week 24

  8. Left atrial volume index

    Change from baseline in left atrial volume index (LAVI, measured in mL/m²) at 12 and 24 weeks

    Time frame: Baseline, Week 12, and Week 24

  9. Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical summary score

    Change from baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical summary score (CSS) at 12 and 24 weeks. a. KCCQ, scored 0 to 100 with higher scores indicating better health.

    Time frame: Baseline, Week 12 and Week 24

  10. Kansas City Cardiomyopathy Questionnaire (KCCQ) Total summary score

    Change from baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Total summary score (TSS) at 12 and 24 weeks. a. KCCQ scored 0 to 100 with higher scores indicating better health.

    Time frame: Baseline, Week 12, and Week 24

  11. Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall summary score

    Change from baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall summary score (OSS) at 12 and 24 weeks. KCCQ, scored 0 to 100 with higher scores indicating better health.

    Time frame: Baseline, Week 12, and Week 24

Other outcomes

  1. Number and percentage of participants with Treatment-emergent adverse event (TEAEs)

    Number and percentage of participants with Treatment-emergent adverse event (TEAEs).

    Time frame: First dose of investigational drug to Week 28 (end-of-study)

07

Study locations

2 of 2 sites recruiting
  • Cardurion Investigative Site
    Pasadena, California 91105, United States
    Recruiting
  • Cardurion Investigative Site
    Bloomfield Hills, Michigan 48304, United States
    Recruiting
08

References and documents

Publications

  • Takagahara, Shuichi, et al. "Novel, Potent, and Highly Selective Calcium/Calmodulin-Dependent Protein Kinase II (CaMKII) Inhibitors Reduce Substrate Phosphorylation in Rat Hearts and Prolong Survival in a Mouse Model of Severe Heart Failure." Circulation 148.Suppl_1 (2023): A12726-A12726. https://doi.org/10.1161/circ.148.suppl_1.12726

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Sep 2028, 26 months after the start.

Of 74 industry-sponsored phase 2 interventional studies under Heart Failure, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 31. This study's planned 26 months is above that.

Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2026
First posted
Aug 6, 2026
StartActual
Jul 15, 2026
Primary completionEst.
Sep 2028
CompletionEst.
Sep 2028
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07750873
Lead sponsor
Cardurion Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Aug 6, 2026
Start date
Jul 15, 2026
Primary completion
Sep 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Aug 6, 2026

Study contacts

Cardurion Pharmaceuticals
Contact
ClinicalTrialsGov@cardurion.com
617-863-8088

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CRD-4730

Start the discussion